On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent [5]

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 4040-

  Shaked, Yuval ^a   Bertolini, Francesco ^a   Emmenegger, Urban ^a   Lee, Christina R ^a   Kerbel, Robert S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; METHOTREXATE; N ACETYLCOLCHINOL PHOSPHATE; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; MCAM PROTEIN, HUMAN; N ACETYLCOCHINOL O PHOSPHATE; N-ACETYLCOCHINOL-O-PHOSPHATE; ORGANOPHOSPHORUS COMPOUND; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; ENDOTHELIUM CELL; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; IMMUNOMAGNETIC SEPARATION; LETTER; LYMPHOCYTE; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL; TUMOR VASCULARIZATION; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; METABOLISM; NOTE; PHASE 1 CLINICAL TRIAL;

ANTIGENS, CD146; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS, PHASE I; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748451328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.1175     Document Type: Letter

References (8)

1. Beerepoot LV, Radema SA, Witteveen EO, et al: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498, 2006
2. St Croix B, Rago C, Velculescu V, et al: Genes expressed in human tumor endothelium. Science 289:1197-1202, 2000
3. Tozer GM, Kanthou C, Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435, 2005
4. Mancuso P, Burlini A, Pruneri G, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661, 2001
5. Duda DG, Cohen KS, di Tomaso, E, et al: Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: Implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24:1449-1453, 2006
6. Elshal MF, Khan SS, Takahashi Y, et al: CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood 106:2923-2924, 2005
7. Mancuso P, Colleoni M, Calieri A, et al: Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108:452-453, 2006
8. Vincent L, Kermani P, Young LM, et al: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006, 2005